Jaume Mora, Alicia Castaneda, Essy Madariegue, Antonio Lopez-Pousa, Claudia María Valverde, Javier Martin Broto, Xavier Garcia del Muro, Javier Martinez Trufero, Josefina Cruz, Joan Maurel, Maria Angeles Vaz, Sara Perez-Jaume, Enrique Alava, Carmen de Torres. GEIS-21: A multicentric phase II study of intensive chemotherapy including gemcitabine/docetaxel for the treatment of Ewing sarcoma of children and adults: A report from the Spanish Group of Sarcoma Investigation (GEIS).
ASCO 2016
Claudia Valverde, Javier Martin, José Antonio López, Cleofé Romagosa, Pilar Sancho, Juan Antonio Carrasco, Andrés Poveda, Sebastian Bauer, Javier Martínez Trufero, Fina Cruz, Peter Reichardt, Pablo Luna, Viktor Grünwald, Oscar Persiva, Diego Varona, Bernd Kasper. Phase II Clinical Trial evaluating the activity and tolerability of Pazopanib in patients (pts) with advanced and/or metastatic liposarcoma (LPS). A joint Spanish Sarcoma Group (GEIS) and German Interdisciplinary Sarcoma Group (GISG) Study.
ASCO 2016
Javier Martin Broto, Antonio Fernandez-Serra, Antonio Lopez-Pousa, Antonio Gutierrez, Ramon De Las Penas, Javier Martinez-Trufero, Josefina Cruz, Rosa Maria Alvarez, Ricardo Cubedo, Andres Redondo, Juan Antonio Carrasco, Jose A. Lopez-Martin, María Ángeles Sala, Isabel Sevilla, Carmen Balana, María Ángeles Vaz Salgado, Ana De Juan, Andres Poveda, Nadia Hindi, Jose Antonio Lopez-Guerrero. CUL4A and ERCC1 genes as predictive factors for trabectedin efficacy in advanced soft tissue sarcomas (STS): A Spanish Group for Sarcoma Research (GEIS) study.
ASCO 2016
Elena Palassini, Stefano Ferrari, Javier Martin Broto, Paolo Verderio, Antonio Lopez-Pousa, Angela Buonadonna, Rosalba Miceli, Silvia Stacchiotti, Angelo Paolo Dei Tos, Antonino De Paoli, Davide Maria Donati, Andres Poveda, Vittorio Quagliuolo, Alessandro Comandone, Stefano Bottelli, Piero Picci, Paolo Giovanni Casali, Alessandro Gronchi. Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): Long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group.
ASCO 2016
J Martin-Broto, A Fernández-Serra, A Gutierrez, I Felipe, J Duran, S Calabuig, D Sanchez-Izquierdo, N Hindi, R Alemany and JA López-Guerrero. GEIS 31: Prognostic impact of COL5A2 and ACVR1B genes in intestinal high risk localized GIST. A Spanish Groups for Research on Sarcoma (GEIS) study.
ASCO 2016
Silvia Stacchiotti, Paolo Verderio, Antonella Messina, Carlo Morosi, Paola Collini, Antonio Llombart-Bosch, Javier Martin, Alessandro Comandone, Jurado Cruz, Stefano Ferrari, Giovanni Grignani, Stefano Bottelli, Vittorio Quagliuolo, Piero Picci, Antonino De Paoli, Angelo Paolo Dei Tos, Paolo G. Casali, Alessandro Gronchi, MD. Tumor response assessment by Choi criteria in localized high-risk soft tissue sarcoma (STS) treated with chemotherapy (CT): update at 10-year follow-up of an exploratory analysis on a Phase III trial.
ASCO 2016
Javier Martin, Elena Fumagalli, Virginia Martínez. Phase II, single-arm, non-randomized and multicenter clinical trial of regorafenib (REG) as a single agent in the first-line setting for patients with metastatic and/or unresectable KIT/PDGFR Wild Type GIST. GEIS and ISG study.
GEIS 40 (REGISTRI). ASCO 2016
A. Gronchi, S. Ferrari, V. Quagliuolo, J. Martin Broto, A. Lopez-Pousa, G. Grignani, V. Ferraresi, J.-Y. Blay, P. Rutkowski, F. Merlo, E. Marchesi, P. Ledesma, A.P. Dei Tos, S. Bague Rosell, J.-M. Coindre, C. Morosi, S. Stacchiotti, P. Picci, P. Bruzzi, P. Casal. LBA6_PR - Full-dose neoadjuvant anthracycline+ifosfamide chemotherapy is associated with a relapse free survival (RFS) and overall survival (OS) benefit in localized high-risk adult soft tissue sarcomas (STS) of the extremities and trunk wall: Interim analysis of a prospective randomized trial.
Oral. Presidential Sympossium. ESMO 2016 Copenhague
N. Hindi; J. Martinez-Trufero; A. Carranza; A. Lopez-Pousa; R. Alvarez; J.L. Arranz; J. Martinez; C. Valverde; J.M. Cano; C. Tous; R. Ribas; R. Gonzalez-Campora; J. Martin-Broto. Exploratory analysis of immunomodulation and apoptosis factors in alveolar soft-part sarcoma: a retrospective study from the Spanish Group for Research on Sarcoma (GEIS).
Oral. CTOS 2016
J. Martin-Broto; M. Mendiola; L. Guerra; A. Gutierrez; I. Felipe; J. Martinez-Trufero; L.M. de Sande Gonzalez; N. Hindi; C. Tous; C. Valverde; A. Casado; R. Ramos; V. Martinez-Marin. GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine/ docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish Group of Sarcoma Investigation (GEIS).
Oral. CTOS 2016
Jaume Mora, MD, PhD; Alicia Castañeda; Antonio Lopez-Pousa; Claudia Valverde; Javier Martin-Broto; Xavier Garcia del Muro; Enrique de Alava; Carmen de Torres. GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine/ docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish Group of Sarcoma Investigation (GEIS).
Póster. CTOS 2016
Nadia Hindi, MD; Pablo Luna; Antonio Lopez-Pousa; Jordi Rubio; Claudia Valverde; Javier Martinez-Trufero; Jeronimo Martinez; Maria Angeles Sala; Juan Luis Arranz; Fatima Toscano; Rosa Alvarez; Juana Maria Cano; Nuria Lainez; Ana de Juan; Javier Martin-Broto. Phase II trial of gemcitabine plus rapamycin as second line in advanced osteosarcoma: A Spanish Group for Sarcoma Research (GEIS) Study.
Póster. CTOS 2016
Javier Martin Broto, Andrés Redondo, Claudia María Valverde, María Ángeles Vaz Salgado, Jaume Mora, Xavier Garcia del Muro, Maria Pilar Sancho Marquez, Javier Martinez-Trufero, Robert Diaz Beveridge, Antonio Gutierrez, Pilar Blay, Cristina Tous, Pablo Luna Fra, Antonio Lopez-Pousa. Phase II trial of gemcitabine plus rapamycin as second line in advanced osteosarcoma: A Spanish Group for Sarcoma Research (GEIS) Study.
ASCO 2015
Javier Martin Broto, Antonio Fernandez-Serra, Jose Duran, Silvia Calabuig-Fariñas, Antonio Gutierrez, Irene Felipe-Abrio, Dolors Sanchez-Izquierdo, Javier Martinez-Trufero, Antonio Casado Herraez, Andres Poveda, Luis Rubio Martinez, Carmen Balana, Ferran Losa, Claudia María Valverde, Jordi Rubió, Josefina Cruz, Luis Miguel Gonzalez de Sande, Cristina Tous, Ricardo Cubedo, Jose Antonio Lopez-Guerrero. Prognostic relevance of miRNA let-7e in localized intestinal GIST: A Spanish Group for Research on Sarcoma (GEIS) Study.
ASCO 2015
Josefina Cruz, Nadia Hindi, Rosa Alvarez, Jose Antonio López, Antonio Gutierrez, Antonio Lopez-Pousa, Maria Jesús Blanco, Javier Martinez-Trufero, Juana Maria Cano, Claudia Valverde, Jerónimo Martínez, Jordi Rubió, Angeles Sala, J Alejandro Perez-Fidalgo, Javier Martin. Visceral angiosarcoma series: differential behaviour between breast angiosarcomas and other locations. A Spanish Group for Sarcoma research (GEIS) study.
CTOS 2015 St Lake City
Josefina Cruz, Nadia Hindi, Rosa Alvarez, Jose Antonio López, Antonio Gutierrez, Antonio Lopez-Pousa, Maria Jesús Blanco, Javier Martinez-Trufero, Juana Maria Cano, Claudia Valverde, Javier Lavernia, Maria Angeles Vaz, Isabel Sevilla, Luis Miguel de Sande Gonzalez, Javier Martin. Somatic localized angiosarcoma: a clinico-pathological series characterization from the Spanish Group for sarcoma research (GEIS).
CTOS 2015 St Lake City
Nadia Hindi, Josefina Cruz, Rosa Álvarez, Juana María Cano, Antonio Gutierrez, Jerónimo Martínez, Antonio Lopez-Pousa, Jose Antonio López, Pablo Luna, Luis Maríz González de Sande, Maria Jesús Blando, Javier Lavernia, Salmvador Martín-Algarra, Javier Martinez-Trufero, Javier Martin. Epithelioide hemangioendotelioma: a retrospective analysis from the spanish Group for sarcoma research (GEIS).
CTOS 2015 St Lake City
Martin Broto J. Prognostic relevance of fas ligand (fasl) in advanced sarcomas. Translational research associated to randomized phase II trial comparing trabectedin-doxorubicin vs doxorubicin. A GEIS study.
CTOS 2014
Martín Broto J. Integrating genotype in risk classification for gist recurrence. A Spanish Group for Sarcoma Research (GEIS) Study.
ESMO 2014
Maurel J. Prognosis of p-IGF-1R and MMP3 expression in advanced GIST patients treated with imatinib. A GEIS study.
ESMO 2014
Cruz F. Solitary Fibrous Tumor (SFT): A registry program (RP) to assess frequency and Management in our country. A Spanish Group for Research on Sarcoma (GEIS) study.
ESMO 2014
Martínez Trufero J. Multidisciplinary treatment outcome of desmoid-type fibromatosis (DTF). A registry-based study from Spanish Group for Research on Sarcoma (GEIS).
ESMO 2014
Garcia del Muro X, López Pousa A, Martínez Trufero J, Martín Broto J, Cubedo R, Lavernia J, Redondo A, López Martín JA, Mulet N, Sanjuan X, Martinez Tirado. O Phase II study of gemcitabine (GEM) plus sirolimus (SIR) in previously treated patients with advanced soft tissue sarcoma (STS): A Spanish Group for Research on Sarcomas (GEIS) study.
J Clin Oncol 32:5s, 2014 (suppl; abstr 10594) ASCO 2014
Martin Broto J, MArtínez Serra J, Ramos R, López Guerrero JA, Bagué S, Martínez C, Álvarez R, García del Muro X, de las Peñas R, Gutiérrez A, Martínez Trufero J, Cruz J, Poveda A, Álvarez R, Cubedo R, Redondo A, Maurel J, Sala MA, López Martín JA, López Pousa. A Prognostic/predictive biomarkers in advanced soft tissue sarcomas (STS): Translational research associated to randomized phase II trial comparing trabectedin-doxorubicin versus doxorubicin—A GEIS study.
Oral Abstract Session, Sarcoma. J Clin Oncol 32:5s, 2014 (suppl; abstr 10500) ASCO 2014
Martin Broto J, Redondo A, Martínez Trufero J, Valverde C, Vaz, MA, Medina J, Obrador A, Felipe I, Castelo B, Hidalgo P, Pajares I, Duran J, Amurrio R, Alemany R. Nilotinib as co-adjuvant treatment with doxorubicin in sarcomas: Phase I trial results—A Spanish Group for Research on Sarcoma (GEIS) study.
J Clin Oncol 32:5s, 2014 (suppl; abstr 10573). ASCO 2014
P Giovanni Casali, A Le Cesne, A Poveda Velasco, D Kotasek, P Rutkowski, P Hohenberger, E Fumagalli, I Robert Judson, A Italiano, J Martin Broto, A Gronchi, A Paolo Dei Tos, S Marreaud, W T.A. Van Der Graaf, J Raymond Zalcberg, S Litière, JY Blay and EORTC Soft Tissue and Bone Sarcoma Group (EORTC STBSG), French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), Grupo Español de Investigación en Sarcomas (GEIS), Australasian Gastro-Intestinal Trials Group (AGITG). Imatinib failure-free survival (IFS) in patients with localized gastrointestinal stromal tumors (GIST) treated with adjuvant imatinib (IM): The EORTC/AGITG/FSG/GEIS/ISG randomized controlled phase III trial.
Poster discussion: Proc Am Soc Clin Oncol. 2013:31;10500
Garcia del Muro, Joan Maurel, Javier Martinez Trufero, Javier Lavernia, A Lopez-Pousa, R De Las Penas, R Cubedo, J Fra, A Casado, A De Juan, L Jimenez Colomo and J Martin Broto. Phase II trial of ifosfamide in combination with sorafenib in patients with advanced soft tissue sarcoma: A Spanish Group for Research on Sarcomas (GEIS) study.
Poster discussion: Proc Am Soc Clin Oncol. 2013:31;10523.
J Martin Broto, R Ramos, J Martinez-Trufero, S Calabuig, C Horndler, A Casado, L Ortega, LM Gonzalez de Sande, F Izquierdo, A Gutierrez, A Sala, A Ugalde, C Valverde, I de Torres, F Losa, Remei Blanco, R Sanchez Gomez, R Cubedo, JA Carrasco, C Balañá and Spanish Group for Research on Sarcomas (GEIS). Prognostic significance of Wnt signaling pathway molecules in nongastric GIST patients: A tissue microarray-based (TMA) analysis.
Poster discussion: Proc Am Soc Clin Oncol. 2013:31;10529.
J. Martin Broto, X. Garcia Del Muro, A. Lopez-Pousa, R. De Las Penas, J. Maurel, R. Cubedo5, A. Redondo, J. Martinez-Trufero, J. Cruz Jurado, A.M. Poveda. Randomized, open, prospective, phase II clinical trial of doxorubicin (Doxo) vs. trabectedin plus Doxo in the first-line treatment of patients (pts) with advanced non-operable and/or metastatic soft tissue sarcomas (STS): GEIS-20 study.
ESMO 2012, 1517.
J Martin Liberal, M Gil, L Jimenez, M Ochoa de Olza, C Munoz, N Gonzalo, R Rigo, H Colom, M Sainz Jaspeado, O M. Tirado and X Garcia del Muro. Phase I study of sirolimus plus gemcitabine in patients with advanced solid tumors: A Spanish Group for Research on Sarcomas (GEIS) study.
Poster discussion: Proc Am Soc Clin Oncol. 2012:30;3096.
X Garcia del Muro, A Lopez-Pousa, MJ Flor, A Redondo, J Cruz Jurado, R Andres, A Casado, J Fra, JA Lopez-Martin, J Maurel, C Valverde, O Gallego, JA Narvaez, S Bague, X Sanjuan and JM Vinyals. Phase II study of neoadjuvant high-dose ifosfamide with concurrent radiotherapy followed by surgical resection in high-risk soft tissue sarcoma: A Spanish Group for Research on Sarcomas (GEIS) study.
Poster discussion: Proc Am Soc Clin Oncol. 2012:30;10052.
J Martin Broto, A Lopez-Pousa, R Ramos, A Gronchi, P Giovanni Casali, A Gutierrez, Piero Picci, S Ferrari, Josefina Cruz, P Luna Fra, Antonio Casado, R Cubedo, R Lasso, Andres Poveda, A De Juan, C Balana, S Calabuig, A Obrador and J Antonio Lopez-Guerrero. Relationship of CUL4A gene underexpression and prognosis in localized high-risk soft tissue sarcoma (STS) patients of limbs or trunk wall.
Poster discussion: Proc Am Soc Clin Oncol. 2012:30;10079.
P.G. Casali, S. Stacchiotti, P. Verderio, P. Collini, A. P. Dei Tos, M. Alberghini, A. Llombart-Bosch, C. Morosi, A. Messina, M. Mercuri and A. Gronchi. Histology and outcome in localized high-risk soft tissue sarcomas (STS) treated with preoperative chemotherapy (CHT) with or without radiation therapy (RT) within a phase III trial from the Italian Sarcoma Group (ISG) and the Spanish Sarcoma Group (GEIS).
Poster discussion: Proc Am Soc Clin Oncol. 2011:29;10089.
S. Stacchiotti, P. Verderio, A. Messina, C. Morosi, A. Ferraro, V. Quagliuolo, J. Martin, A. Comandone, G. Grignani, P. Picci, S. Frustaci, A. Gronchi and P. G. Casali. Tumor response and outcome in localized high-risk soft tissue sarcomas (STS) treated with preoperative chemotherapy (CHT) with or without radiation therapy (RT) within a phase III trial from the Italian Sarcoma Group (ISG) and the Spanish Sarcoma Group (GEIS).
Poster discussion: Proc Am Soc Clin Oncol 2011:29;10019.
J. Rubió, J. Martinez-Trufero, A. Lopez-Pousa, X. Garcia del Muro, J. Fra, A. Redondo, N. Lainez, A. Poveda, A. Casado, C. M. Valverde, A. De Juan, I. Sevilla, R. Andres, J. Cruz, M. J. Safont, J. Martin Broto, X. Garcia-Albeniz and J. Maurel. Retrospective analysis of surgery in metastatic GIST patients sensitive to imatinib: A Spanish Group for Research on Sarcoma (GEIS) study.
Poster discussion: Proc Am Soc Clin Oncol 2011:29;10055.
J. Martin Broto, X. Garcia del Muro, A. Gutierrez, J. Martinez-Trufero, T. Serrano, J. Rubió, N. Lainez, I. Sevilla, J. Cruz, R. Ramos, L. Ortega, A. Poveda, M. Ramirez, R. Cubedo, J. Lopez-Guerrero and Spanish Group for Sarcoma Research (GEIS). KIT, DOG1, PDGFR, and IGFR1 gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patients.
Poster discussion: Proc Am Soc Clin Oncol 2011:29;10047.
Lopez-Pousa, B. Bui Nguyen, X. Garcia del Muro, J. Martin Broto, C. Balañá, J. Lavernia, J. Cruz, J. Maurel, R. Andres, C. M. Valverde, J. Fra, J. Martinez-Trufero, J. A. Lopez-Martin, I. Sevilla, R. Cubedo and J. Blay. A phase II study of a new formulation of nonpegylated liposomal doxorubicin (doxorubicin GP-pharm) as first-line treatment in patients with advanced soft-tissue sarcomas (STS) who are age 65 or older: A GEIS trial.
Poster discussion: Proc Am Soc Clin Oncol 2011:29;10072.
J. Martin Broto, X. Garcia del Muro, J. Rubio, A. Gutierrez, J. Martinez-Trufero, I. Sevilla, N. Lainez, R. Andres, R. Ramos and J. A. Lopez-Guerrero. Prognostic factors of KIT-negative GIST-like patients (KNGL): A Spanish Group for Sarcoma Research (GEIS) study.
Poster discussion: Proc Am Soc Clin Oncol 2010:28;10070.
X. Garcia del Muro, A. Lopez-Pousa, J. Martin Broto, R. Cubedo, L. Jimenez Colomo, O. Gallego and M. Provencio-Pulla. Phase I study of sorafenib plus ifosfamide in patients with advanced soft tissue and bone sarcoma: A Spanish Group for Research on Sarcomas (GEIS) study.
Poster discussion: Proc Am Soc Clin Oncol 2010:28;10024.
Gronchi, S. Frustaci, M. Mercuri, J. Martin Broto, A. Lopez-Pousa, L. Mariani, P. Verderio, V. Quagliuolo, P. G. Casali and P. Picci. Localized, high-risk soft tissue sarcomas (STS) of the extremities and trunk wall in adults: Three versus five cycles of full-dose anthracyclin and ifosfamide adjuvant chemotherapy: A phase III randomized trial from the Italian Sarcoma Group (ISG) and Spanish Sarcoma Group (GEIS).
Poster discussion: Proc Am Soc Clin Oncol 2010:28;10003.
X. Garcia Del Muro, J. Fra, A. Lopez Pousa, J. Maurel, J. Martín, J. Martínez Trufero, A. Casado, J. Cruz, M. A. Gómez España and J. Lavernia. Randomized phase II study of dacarbazine plus gemcitabine versus DTIC alone in patients with advanced soft tissue sarcoma: A Spanish Group for Research on Sarcomas (GEIS) study.
Poster discussion: Proc Am Soc Clin Oncol 2009:26;10529.
D. Fuster, A. Sierra, J. R. Ayuso, A. Poveda, R. Cubedo, A. Casado, J. Martínez-Trufero, A. López-Pousa, X. Garcia Del Muro and J. Maurel. Correlation between spiral CT and PET in patients with advanced GIST refractory to high-dose imatinib: A GEIS study.
Poster discussion: Proc Am Soc Clin Oncol2009:27;10553.
A Lopez Pousa; J. Martin; C. Balaña; A. Poveda; J. Garcia del Muro; J. Maurel; R. Cubedo. Phase I-II study of a new formulation of non-pegylated liposomal doxorubicin (doxo Gp-pharm) as first-line treatment of older patients with advanced soft-tissue sarcomas (STS): a GEIS study. Spanish Group for Research in Sarcomas, Geis, Spain.
14th CTOS Annual Scientific Meeting, London, November 2008; 35129.
Poveda, J. Maurel, R. Cubedo, A. Casado, J. Ayuso, D. Fuster, J. Martinez-Trufero, A. Lopez-Pousa, J. Martin and X. Garcia del Muro. Phase I-II trial of imatinib (IM) and low-dose doxorubicin (DX) in patients (pts) with advanced gastrointestinal stromal tumors (GIST), refractory to high-dose IM: A GEIS Study.
Poster discussion: Proc Am Soc Clin Oncol 2008:26;10520.
J. Maurel, A. Lopez-Pousa, R. de las Peñas, J. Fra, J. Cruz, J. Martin, A. Casado, J. Martinez-Trufero, A. Poveda and X. Garcia del Muro. Standard-dose doxorubicin versus sequential dose-dense doxorubicin and ifosfamide in patients with untreated advanced soft tissue sarcoma (ASTS): A GEIS Study.
Poster discussion: Proc Am Soc Clin Oncol 2008:26;10570.
J. Martin, A. Gutierrez, J. Garcia del Muro, J. Maurel, L. M. Gonzalez de Sande, J. Martinez, A. De Juan, N. Lainez, F. Losa and A. Poveda. Time dependence of critical deletions as prognostic factor for relapse-free survival (RFS) in localised GIST. A Spanish Group for Sarcoma Research (GEIS) study.
Poster discussion: Proc Am Soc Clin Oncol 2008:25;10508.
Romero, A. Poveda, J. Martin, A. Lopez-Pousa, C. Gomez, M. Safont, R. Andres, V. Guillem, A. Llombart-Bosch and J. Lopez-Guerrero. Pathological significance of deletions involving codons 557 and 558 of KIT gene in localized resected gastrointestinal stromal tumors (GIST) of intermediate and high risk: A study by the Spanish Group for Sarcoma Research (GEIS).
Poster discussion: Proc Am Soc Clin Oncol 2007:25;10051.
García del Muro X, Poveda A, Buesa JM, Martínez-Trufero J, González de Sande LM, Calvo E, Escudero P, López-Pousa A, Fabregat X, Casado A. Phase II Trial of Temozolomide as First-line Treatment for Patients with Advanced Gynecological Sarcoma: A Spanish Group for Research on Sarcomas (GEIS) and Spanish Ovarian Cancer Research Group (GEICO) Study.
Poster Discussion. Proc Am Soc Clin Oncol 2006 juny Atlanta.
García del Muro X, Fra F, Martínez-Trufero J, Sevilla I, Escudero P, Cruz J, Martín J, Casado A, Arrazubi V, Buesa JM. Temozolomide in the treatment of gynecological leiomyosarcoma: A Spanish Group for Resarch in Sarcomas (GEIS) study.
Poster Discussion. Proc Am Soc Clin Oncol 2005;22:9030.
López-Pousa A, Buesa JM, Casado A, García del Muro X, Poveda A, Maurel J, Martín J, Balañá C, Martínez-Trufero J, Martín J, Poveda A, Llombart-Bosch A, Ramos R, García del Muro X, Martínez-Trufero J. Doxorubicin (DXR) and prolonged infusion gemcitabine (GMC) as first-line treatment in advanced soft tissue sarcomas (STS). A phase II trial of the Spanish Group for Resarch in Sarcomas (GEIS).
General Poster Session. Proc Am Soc Clin Oncol 2004;22:9033.
Martín J, Poveda A, Llombart-Bosch A, Ramos R, García del Muro X, Martínez-Trufero J, de Juan A, Maurel J, Losa F, Buesa JM. Prognostic value of pathologic variables and mutations type in patients with complete surgical resection of gastrointestinal stromal tumors (GIST). A GEIS study.
General Poster Session. Proc Am Soc Clin Oncol 2004;22:9029.
Buesa JM, Fra J, López-Pousa A, Losa R, Mareque B, Sierra M, Una E, Blay P. Phase I trial of Dacarbacine (DTIC) and prolonged infusion Gemcitabine in patients with soft Tissue sarcoma.
Poster Discussion. Proc Am Soc Clin Oncol vol 2003;22:3296.
López-Pousa A, Buesa JM, Martín J, Casado A, Balañá C, García del Muro X, Poveda A. Phase I/II trial of Doxorubicin and dose escalation prolonged infusion Gemcitabine as first line treatment in advanced soft tissue sarcomas. A study of the Spanish Group for Research in Sarcomas (GEIS).
General Poster Session. Proc. Am Soc Clin Oncol 2003; 22(825):3317.
Martín J, López-Pousa A, Bover I, Sevilla I, Cruz J, Buesa JM, Escudero P, Blanco R, Poveda A, Casado A, García del Muro X, Maurel J, Piera JM, Maestu I, Casado S, Carles J, González de Sande LM, Montalar J, Martínez-Trufero J, de las Peñas R, Rifa J. Malignant Gastointestinal stromal tumors and uterine sarcomas: differences in prognostic factors for survival. A clinical approach. Study of the Spanish Group for Research in sarcomas (GEIS).
Poster Discussion. Proc Am Soc Clin Oncol 2002;21(411ª):a-1641.
Buesa JM, Teijido PG, Fra J, et al. Treatment of ifosfamide (IFOS) encephalopathy with intravenous thiamine.
Poster Discussion. Proc Am Soc Clin Oncol 2002;21:409,a.
Maurel J, Buesa JM, López-Pousa A, García del Muro X, Martínez-Trufero J, de las Peñas R, Escudero P, Piera JM, Martín J, Casado A, Sevilla I, Balañá C, Bover I, Montalar J, Poveda A, Cassinello J, Cruz J, Carles J, Camps C, Bellmunt J. High-dose ifosfamide (HDIF) based regimens in advanced soft tissue sarcoma patients. An analysis of prognostic factors: A study of the Spanish Group for Research on Sarcomas (GEIS).
Proc Am Soc Clin Oncol 2002;21(407ª):a-1627.
García del Muro X, López-Pousa A, Buesa JM, Martín J, Poveda A, Bover I, Escudero P, Martínez-Trufero J, Casado A. Temozolomide as a 6-week continuous oral schedule in advanced soft tissue sarcoma: A phase II trial of the Spanish Group for Research on Sarcomas (GEIS).
2001 CTOS Annual Meeting Posters— Medical Oncology.
García del Muro X, López-Pousa A, Buesa JM, Martín J, Poveda A, Bover I, Escudero P, Martínez-Trufero J, Casado A. Temozolomide as a 6 week continuous oral schedule in advanced soft tissue sarcomas: A phase II study of the Spanish Group for Research on Sarcomas (GEIS).
Proc. Am Soc Clin Oncol 2001; 20: 1412.
López-Pousa A, Buesa JM, García del Muro X, et al. Sequential high-dose doxorubicin (Dx) and High dose Ifosfamide (IF) in advanced previosly untreated soft tissue sarcoma of the adult (STS). A multicenter phase II study of the Spanish Group for Research on Sarcomas (GEIS).
Proc Am Soc Clin Oncol 2001;20:353.
García del Muro X, López-Pousa A, Buesa JM, Martín J, Bover I, Escudero P, Casado A, Martínez-Trufero J, Maurel J. Temozolomide as a 6-week continuous oral schedule in advanced soft tissue sarcomas: a phase II study of the Spanish Group for Reseach in Sarcomas (GEIS).
Poster – Discussion. 37th ASCO Annual Meeting. San Francisco, mayo 2001. Proc Am Soc Clin Oncol 2001;20:354a.
López-Pousa A, Buesa JM, García del Muro X, Manuel J, Balañá C, Casado A, Bellmunt J, Poveda A, Martín J, Martínez-Trufero J, de las Peñas R, Bover I. Sequential High-dose Doxorubicin and High-dose Ifosfamide in advanced previously untreated soft tissue sarcomas of the adult. A multicenter phase II study of the Spanish Group for Reseach in Sarcomas (GEIS).
Poster – Discussion. 37th ASCO Annual Meeting. San Francisco, mayo 2001. Proc Am Soc Clin Oncol 2001;20:353a
López-Pousa A, Buesa JM, Montalar J, Martín J, Maurel J, García del Muro X, de las Peñas R, Cruz J, Cassinello J, Sevilla I, Balañá C, Casado A. First-line Doxorubicin and scalated High-dose Ifosfamide in advanced soft tissue sarcoma patients a phase II study of the Spanish Group for Research in Sarcomas (GEIS).
Comunicación-Poster- Sesion. 36th ASCO New Orleans, Louisiana, mayo 2000.
Buesa JM, Teijido PG, Galbe M, López-Pousa A, García del Muro X; Martín J, Antón A, Montalar J, de las Peñas R, Cruz J, Escudero P, Fra J, Menéndez D, Poveda A. Nephrotoxicity of continuous infusion ifosfamide. A study of the Spanish Group for Research on Sarcomas (GEIS)”.
Abstract 0037. 5th CTOS congress. Arlington, Octubre 1999.
Poveda A, López-Pousa A, Martín J, Buesa JM, Balañá C, Menéndez D. Liposomal Doxorubicin (Caelyx) in advanced soft tissue sarcoma patients. A phase II study of the Spanish Group for Research in Sarcomas (GEIS).
Comunicación. 36th ASCO. Atlanta, mayo 1999. Proc Am Soc Clin Oncol 1999;18:553a.
López-Pousa A, Buesa JM, Montalar J, Martín J, Maurel J, García del Muro X, de las Peñas R, Cruz J, Cassinello J, Sevilla I, Balañá C, Casado A, Bover I, Paredes A, Carles J, Poveda A. Phase II trial of Doxorubicin and High-dose Ifosfamide in advanced previously untreated soft tissue sarcoma patients. a study of the Spanish Group for Research in Sarcomas (GEIS).
Poster Discussion. 36th ASCO. Atlanta, mayo 1999. Proc Am Soc Clin Oncol 1999;18:544a.
López-Pousa A, Montalar J, Buesa JM, Maurel J, Martín J, Cassinello J; Sevilla I; de las Peñas R, Cruz J, Balañá C. First-line doxorubicin and high-dose ifosfamide (DHI) in advanced soft tissue sarcoma (STS) patients. A phase II study of the Spanish Group for Research on Sarcomas.
Abstract 564. 23rd ESMO Congress. Atenas, Noviembre 1998.
López-Pousa A, Montalar J, Buesa JM, Maurel J, Martín J, Cassinello J, Sevilla I, de las Peñas R, Cruz J, Balañá C, García del Muro X, Poveda A. High-Dose Ifosfamide and Doxorubicin in advanced previously untreated soft tissue sarcoma patients. a phase II study of the Spanish Group for Research in Sarcomas (GEIS).
4th CTOS Annual Scientific Meeting. Vancouver, November 1998.
Buesa JM, López-Pousa A, Antón A, Martín J, García del Muro X, Bellmunt J, Poveda A, Escudero P. Phase II trial of first–line high-dose Ifosfamide in advanced soft tissue sarcoma (STS) patients.
Poster. 33nd ASCO. Denver, Mayo 1997. Proc Am Soc Clin Oncol 1997;16:498a.